- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01356758
Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents
Psoriasis is a common inflammatory disease of the skin and joints with a prevalence of 1-3% in the caucasian population of Northern Europe and the US. Similarly to other inflammatory diseases there is now substantial and accumulating evidence that psoriasis has a systemic inflammatory component.
It is known that patients suffering from psoriasis have increased prevalence of traditional cardiovascular risk factors, such as hypertension, dyslipidaemia, obesity, tobacco use and diabetes mellitus. This would logically explain an increased rate of cardiovascular events, but even when adjusting for theses risk factors, psoriasis carry an independent risk for developing cardiovascular disease.
Recent large epidemiological studies have shown a strong correlation between psoriasis and myocardial infarction.
Atopic dermatitis has been linked to ischemic stroke in one study, but besides this, the disease has not been associated with cardiovascular disease.
In conclusion, convincing and increasing evidence is supporting that psoriasis induce accelerated atherosclerosis and hence cardiovascular disease and mortality. In particular, this is seen in young patients with early disease onset.
Psoriasis is believed to be driven by cytokines produced by Th1 and Th17 lymphocytes. A number of these cytokines are suggested to be atherogenic. In contrast, another chronic inflammatory disease, atopic dermatitis, is predominantly driven by Th2 lymphocyte derived cytokines, some of which may inhibit atherosclerotic processes. It is therefore, of interest to compare the presence of cardiovascular disease in these two inflammatory skin diseases.
Hypothesis: That the risk of developing cardiovascular disease and especially coronary artery disease is increased in psoriasis patients and that this process can be influenced by treatment of psoriasis with biological treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Aarhus C, Denmark, 8000
- Dep. of Dermatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Males and females aged 18 years or above.
- Intervention group: Severe plaque psoriasis with indication for biological therapy according to national guidelines. Psoriasis Control group: Patients with similar disease activity who for personal reasons decline systemic treatment and only receive topical therapy. Atopic dermatitis group: Patients matched regarding sex, disease duration, body surface involvement, BMI and smoking habits.
- Signed informed consent form prior to initiation of any study-mandated procedure.
Exclusion Criteria:
- Significant arterial hypertension, unless well controlled with anti-hypertensive medication for at least 1 month before inclusion.
- Lipid-lowering treatment, unless well controlled for at least 1 month before inclusion.
- Congestive heart failure (NYHA group III and IV).
- Reduced kidney function (eGFR below 60).
- Oral methotrexate, ciclosporin, acitretin and fumarate esters within 1 month before inclusion. In the intervention group, patients receiving oral anti-psoriatic treatment for at least 6 months before the study start can be included, if they are maintained on the same dose during the study period.
- UVB phototherapy and PUVA photochemotherapy within 1 month prior to study start.
- Prior treatment with infliximab, etanercept, adalimumab or ustekinumab unless less than PASI-50% reduction have been observed during this treatment.
- Investigational biological agents within 6 months prior to inclusion.
- Any other investigational drug within 1 month or 5 half lives prior to inclusion, which ever is longer.
- Concurrent immunosuppressive or anti-inflammatory treatment for immune diseases other than psoriasis and psoriatic arthritis.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Psoriasis topical treatment
Psoriasis topical treatment.
No systemic drugs.
|
|
Psoriasis biological treatment
Psoriasis biological treatment.
Anti-Tnf and anti-il12/23.
|
patients treated with anti-psoriatic biological agents
Other Names:
|
Severe atopic dermatitis
|
|
Control
No intervention.
No inflammatory skin disease.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in coronary calcium score (CAC score)
Time Frame: baseline: 0 months, and follow-up: approximately 12 months
|
Psoriasis groups evaluated at 0 and approximately 12 months.
AD group and controls at baseline only.
|
baseline: 0 months, and follow-up: approximately 12 months
|
Repeated Coronary CT Angiography (CCTA)
Time Frame: 0 and approximately 12 months
|
Assessment according to the 18-segment model (as suggested by AHA): Changes in number of coronary plaques, stenosis, severity, composition. Changes in coronary plaque volume index. Psoriasis groups evaluated at 0 and approximately 12 months. AD group and untreated controls at baseline only. |
0 and approximately 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiovascular risk markers
Time Frame: 0, 3 and 12 months
|
hs-crp, homocystein, SBHG, apolipoprotein B, MBL, PAPP-A.
|
0, 3 and 12 months
|
interleukines in blood
Time Frame: 0, 3 and 12 months
|
selected cytokines (amongst: TNFα, IL-1, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, IL17A, IL-19, IL-20, IL-23, IFN, ICAM-1, E-selectin)
|
0, 3 and 12 months
|
traditional cardiovascular risk factors
Time Frame: 0, 3 and 12 months
|
monitoring of blood cholesterol levels and blood glucose.
|
0, 3 and 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kasper F Hjuler, M.D., Aarhus University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Skin Diseases, Papulosquamous
- Psoriasis
- Dermatitis
- Atherosclerosis
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gastrointestinal Agents
- Dermatologic Agents
- Etanercept
- Adalimumab
- Infliximab
- Ustekinumab
Other Study ID Numbers
- j-nr 20100249
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atherosclerosis
-
University Hospital, CaenUnknownPeripheral Arterial Disease | Atherosclerosis Obliterans | Atherosclerosis Right Leg | Atherosclerosis Left LegFrance
-
Nantes University HospitalAbbottCompletedAtherosclerosis ObliteransFrance
-
Central Hospital, Nancy, FranceSuspended
-
Federal University of São PauloCompletedAtherosclerosis of ArteryBrazil
-
MedtronicActive, not recruitingAtherosclerosis of Femoral Artery | Obstructive Disease | Atherosclerosis of Popliteal ArteryFrance
-
Korea UniversityMinistry of Health & Welfare, KoreaCompletedAtherosclerosis | Noninvasive Imaging of AtherosclerosisKorea, Republic of
-
Cabinet de Medecine Interne Générale Demetrio PitarchCompletedAtherosclerosis of Artery
-
Emory UniversityThe Robert W. Woodruff FoundationCompleted
-
Zhejiang Zylox Medical Device Co., Ltd.RecruitingAtherosclerosis of Femoral ArteryGermany
-
VA Office of Research and DevelopmentCompletedSaphenous Vein Graft AtherosclerosisUnited States
Clinical Trials on biological treatment
-
Centre Hospitalier Universitaire de BesanconRecruiting
-
University Hospital, MontpellierRecruitingLymphoma and Acute Lymphoblastic LeukemiaFrance
-
Centre Hospitalier Universitaire DijonRecruitingAutoimmune Hemolytic Anemia | Venous Thromboembolic Disease | Prolonged AnticoagulationFrance
-
Uppsala UniversityCompletedSpinal Fractures | Ankylosing Spondylitis
-
Centre Hospitalier Universitaire DijonCompletedHyperlactatemia | Actue Circulatory FailureFrance
-
Hospices Civils de LyonUnknownBone Metastases | Thyroid Cancer
-
University Hospital, BordeauxCompletedArrhythmia | SARS-CoV-2 InfectionFrance
-
Centre Hospitalier Universitaire DijonRecruiting
-
AstraZenecaActive, not recruiting
-
Philipps University Marburg Medical CenterPsychotherapie-Ambulanz Marburg e.V.CompletedCondition: Major Depressive Disorder (MDD)Germany